Do crossover and post-progression treatments bias the relationship between surrogate endpoints and overall survival? In two recent studies, we looked at evidence from 317 trials (78,644 patients) in first-line NSCLC setting (study 1 here) and 146 trials (43,061 patients) in further-line NSCLC setting (study 2 here). The relationship between surrogate endpoints, progression-free survival (PFS) and objective
On 23-24 June, the Ingress-health team participated in a charity event organized by KWF Kanker Bestrijding. By taking turns, our team has walked continuously for 24 hours in Papendrecht, the Netherlands. Additionally, we set up a booth where we took Polaroid pictures and made balloon animals for children. We managed to raise an impressive amount of
Together with the local home for asylum seekers, the German office of Ingress-health will be participating in a volleyball tournament on July 12th, 2017 in Wismar. This event is part of Ingress’ vision to encourage its team to maintain its work-life balance. Therefore, the team participates at regular sports events throughout the year. As part
More and more potentially curative interventions become available in oncology. Thus, a growing proportion of cancer patients might indeed be cured of their disease. For reimbursement decisions, it is common practice to estimate long-term overall survival based on trial data and for instance parametric survival curves. These standard parametric methods, however, do not explicitly take
Payers are more interested in effectiveness rather than efficacy of novel treatments. In light of health economics, cost-effectiveness is preferred over cost-efficacy. We aim to assess the use of real-world effectiveness evidence along with efficacy data reported in a clinical trial setting, to estimate effectiveness in a real-world setting with the example of overall survival
The Ingress-health team in the German office will be participating in this year’s relay marathon at Rostock’s marathon night on August 5th, 2017. In a team of 8, we will split the distance of a marathon into shares. The marathon will start at 6 pm and lead the runners through the historic town of Rostock.
Ingress-health first participated in the “Schwedenlauf” – (a local run celebrating the festivities in memory of Wismar’s affiliation to Sweden during and after the thirty years war in the 17th century) – in 2016 and wants to make it a tradition from participating in this run every year. This years’ “Schwedenlauf” will take place on
Due to immaturity of survival data in clinical trials at time of health technology assessment, long-term predictions of survival result in uncertainty in decision-making. To predict survival more accurately, we test Bayesian methods using historical data to inform parametric survival predictions based on immature trial data.
The latest manuscript of the INGRESS Real-world data analysis team published addressed the treatment of German focal epilepsy patients – Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs. Based on a claims dataset with a total of 34,422 patients diagnosed